Bel Reports Third Quarter 2025 Results

(NASDAQ:BELFA),(NASDAQ:BELFB), Sales and Gross Margin Percentage Above Mid-Point of Expected RangesProvides Q4-25 Sales and Gross Margin Guidance WEST ORANGE, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) — Bel Fuse Inc. (Nasdaq: BELFA and BELFB) today announced preliminary financial results for the third quarter of 2025. Third Quarter 2025 Highlights Net sales of $179.0 million compared to […]

Global Ship Lease Announces Third Quarter 2025 Earnings Release, Conference Call and Webcast

(NYSE:GSL), ATHENS, Greece, Oct. 29, 2025 (GLOBE NEWSWIRE) — Global Ship Lease, Inc. (NYSE:GSL) (the “Company”), a containership owner and lessor, announced today that it will hold a conference call to discuss the Company's results for the third quarter 2025 on Monday, November 10, 2025 at 10:30 a.m. Eastern Time. The Company will issue financial

Orange County Bancorp, Inc. Announces Record Third Quarter 2025 Results

(NASDAQ:OBT), Net Income rose $6.8 million, or 211.5%, to $10.0 million for the quarter ended September 30, 2025 as compared to $3.2 million for the quarter ended September 30, 2024 Net Interest Income increased $4.0 million, or 17.3%, to $27.0 million for the quarter ended September 30, 2025, from $23.0 million for the quarter ended

AVITA Medical to Announce Third Quarter 2025 Financial Results

(AUST:AVH.AX),(NASDAQ:RCEL), VALENCIA, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its third quarter 2025 financial results after the close of the U.S. financial markets on Thursday, November 6,

Dayforce Reports Third Quarter 2025 Results

(NYSE:DAY),(TSX:DAY), Dayforce(R) recurring revenue, excluding float, of $333 million, up 14% on a GAAP and constant currency basis Total revenue of $482 million, up 10%, and excluding float, up 11%, or 12% on a constant currency basis Year-to-date net cash provided by operating activities of $194 million MINNEAPOLIS and TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE)

KRONOS WORLDWIDE, INC. ANNOUNCES QUARTERLY DIVIDEND

(NYSE:KRO), Dallas, Texas, Oct. 29, 2025 (GLOBE NEWSWIRE) — DALLAS, TEXAS – October 29, 2025 – Kronos Worldwide, Inc. (NYSE: KRO) announced that its board of directors has declared a regular quarterly dividend of five cents ($0.05) per share on its common stock, payable on December 11, 2025 to stockholders of record at the close

Trupanion Publishes 2025 Corporate Social Responsibility Report

(NasdaqGM:TRUP), SEATTLE, Oct. 29, 2025 (GLOBE NEWSWIRE) — Trupanion, Inc. (Nasdaq: TRUP), a leader in medical insurance for cats and dogs, announced today that they have published their fifth corporate social responsibility report. The report is now available on Trupanion's Investor Relations website here. About Trupanion Trupanion is a leader in medical insurance for cats

FinWise Bancorp Reports Third Quarter 2025 Results

(NasdaqGM:FINW), – Loan Originations of $1.8 Billion –– Net Income of $4.9 Million –– Diluted Earnings Per Share of $0.34 – MURRAY, Utah, Oct. 29, 2025 (GLOBE NEWSWIRE) — FinWise Bancorp (NASDAQ: FINW) (“FinWise”, the “Company”, “we”, “our”, or “us”), parent company of FinWise Bank (the “Bank”), today announced results for the quarter ended September

Aecon reports third quarter 2025 results

Aecon reports third quarter 2025 results GlobeNewswire October 29, 2025 TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) — Aecon Group Inc. (TSX: ARE) (“Aecon” or the “Company”) today reported results for the third quarter of 2025. “Aecon achieved 20% revenue growth, added to record backlog, and is strategically positioned to support the delivery of critical infrastructure

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day GlobeNewswire October 29, 2025 Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models;

Scroll to Top